Abeona Therapeutics Inc. revenue
Abeona Therapeutics Inc.'s revenue was $5.8m in fiscal 2025, up 66.3% on the year before. Since fiscal 2010 ($481,000) it has grown at a compound 21.1% a year. Over the last twelve months it was $25.5m.
Revenue history
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 2 | 4 | 2 | 1 | 1 | 1 | 1 | 3 | 10 | 3 | 1 | 4 | 6 | 26 |
| Growth on the year before | — | +282.3% | +139.5% | −53.6% | −54.7% | +12.4% | −14.5% | −5.8% | +258.2% | +233.6% | −70.0% | −52.9% | +147.5% | +66.3% | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 17 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — | — | 73.7% | 67.1% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Licenses | $3.4M | 58.4% | — |
| Products | $2.4M | 41.6% | — |
From Abeona Therapeutics Inc.'s 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Abeona Therapeutics Inc. | $25.5m | -87.7% | 212.0% |
| Crispr Therapeutics AG | $25.2m | -34.3% | -47.1% |
| Janux Therapeutics, Inc. | $24.0m | 5367.0% | 45.7% |
| Stoke Therapeutics, Inc. | $27.6m | -86.2% | 46.1% |
| Monte Rosa Therapeutics, Inc. | $28.7m | -83.9% | — |
| Tonix Pharmaceuticals Holding Corp. | $29.1m | 196.0% | — |
Compare with peers
- Crispr Therapeutics AG revenue
- Janux Therapeutics, Inc. revenue
- Stoke Therapeutics, Inc. revenue
- Monte Rosa Therapeutics, Inc. revenue
- Tonix Pharmaceuticals Holding Corp. revenue
Head to head: ABEO vs CRSPABEO vs JANXABEO vs STOK
More: Biotechnology stocks compared, Health Care sector, rankings of US companies